Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

110.42USD
13 Dec 2019
Change (% chg)

$-2.05 (-1.82%)
Prev Close
$112.47
Open
$112.82
Day's High
$113.75
Day's Low
$109.72
Volume
547,793
Avg. Vol
734,268
52-wk High
$141.81
52-wk Low
$92.57

Latest Key Developments (Source: Significant Developments)

Alexion Pharmaceuticals Q3 Non-GAAP Earnings Per Share $2.79
Wednesday, 23 Oct 2019 

Oct 23 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS THIRD QUARTER 2019 RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $2.79.Q3 GAAP EARNINGS PER SHARE $2.08.Q3 REVENUE $1.263 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.24 BILLION.Q3 EARNINGS PER SHARE ESTIMATE $2.47 -- REFINITIV IBES DATA.ALEXION PHARMACEUTICALS - NEGATIVE IMPACT OF FOREIGN CURRENCY ON QTRLY TOTAL REVENUE YEAR-OVER-YEAR WAS LESS THAN 1%, OR $2.5 MILLION.INCREASING 2019 REVENUES AND EPS GUIDANCE.SEES 2019 TOTAL REVENUES $4,860 MILLION TO $4,890 MILLION.SEES 2019 GAAP EARNINGS PER SHARE $8.58 TO $8.78.SEES 2019 NON-GAAP EARNINGS PER SHARE $10.25 TO $10.40.ALEXION PHARMACEUTICALS - UPDATED 2019 GUIDANCE ASSUMES GAAP EFFECTIVE TAX RATE OF 5% TO 6% & NON-GAAP EFFECTIVE TAX RATE OF 13% TO 14% FOR YEAR.UPDATED GUIDANCE EXCLUDES FINANCIAL IMPACT OF AGREEMENT TO ACQUIRE ACHILLION.FY2019 EARNINGS PER SHARE VIEW $9.94, REVENUE VIEW $4.85 BILLION -- REFINITIV IBES DATA.  Full Article

Alexion Receives FDA Approval For Ultomiris For Atypical Hemolytic Uremic Syndrome
Saturday, 19 Oct 2019 

Oct 18 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION RECEIVES FDA APPROVAL FOR ULTOMIRIS® (RAVULIZUMAB-CWVZ) FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS).ALEXION PHARMACEUTICALS- REGULATORY FILINGS FOR MARKETING AUTHORIZATIONS OF ULTOMIRIS FOR TREATMENT OF AHUS IN EU, JAPAN UNDER REVIEW WITH REGULATORS.  Full Article

Alexion Pharmaceuticals Says If Merger With Achillion Terminated Under Certain Circumstances, Achillion May Be Required To Pay Co Fee Equal To $20 Million
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION PHARMACEUTICALS - IF MERGER WITH ACHILLION TERMINATED UNDER CERTAIN CIRCUMSTANCES, ACHILLION MAY BE REQUIRED TO PAY CO FEE EQUAL TO $20 MILLION.ALEXION - TO PAY ACHILLION TERMINATION FEE EQUAL TO $30 MILLION, $40 MILLION, $50 MILLION OR $60 MILLION DEPENDING ON EXTENSION OF MERGER END DATE, TERMINATION DATE.  Full Article

Alexion To Acquire Achillion
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - Achillion Pharmaceuticals Inc ::ALEXION TO ACQUIRE ACHILLION.ACHILLION PHARMACEUTICALS INC - INITIAL ALL-CASH TRANSACTION FOR $6.30 PER SHARE.ACHILLION PHARMACEUTICALS INC - DEAL FOR $6.30 PER SHARE.ACHILLION PHARMACEUTICALS INC - TOTAL TRANSACTION OF UP TO $8.30 PER SHARE WITH POTENTIAL ADDITIONAL CONTINGENT CONSIDERATIONS.ACHILLION PHARMACEUTICALS INC - INITIAL DEAL CONSIDERATION OF APPROXIMATELY $930 MILLION.ACHILLION PHARMACEUTICALS INC - ALEXION WILL ALSO BE ACQUIRING CASH CURRENTLY ON ACHILLION'S BALANCE SHEET.ACHILLION PHARMACEUTICALS - DEAL INCLUDES POTENTIAL FOR ADDITIONAL CONSIDERATION IN FORM OF NON-TRADEABLE CONTINGENT VALUE RIGHTS.ACHILLION PHARMA - AS OF SEPT. 30, 2019, CASH CURRENTLY ON ACHILLION'S BALANCE SHEET WAS ABOUT $230 MILLION.ACHILLION PHARMA - CVRS WILL BE PAID TO ACHILLION SHAREHOLDERS IF SOME CLINICAL & REGULATORY MILESTONES ARE ACHIEVED WITHIN SPECIFIED PERIODS.  Full Article

Alexion And Bridgebio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis Investigational Medicine
Monday, 9 Sep 2019 

Sept 9 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND BRIDGEBIO ANNOUNCE JAPANESE LICENSE AGREEMENT FOR EIDOS’ TRANSTHYRETIN AMYLOIDOSIS (ATTR) INVESTIGATIONAL MEDICINE.ALEXION PHARMACEUTICALS INC - EIDOS GRANTS ALEXION EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE AG10 IN JAPAN.ALEXION PHARMACEUTICALS - EIDOS TO RECEIVE UPFRONT PAYMENT OF $25 MILLION AND EQUITY INVESTMENT OF $25 MILLION.ALEXION PHARMACEUTICALS INC - PHASE 3 STUDY OF AG10 IN ATTR CARDIOMYOPATHY UNDERWAY IN U.S. & EUROPE.ALEXION PHARMACEUTICALS INC - PHASE 3 TRIAL IN ATTR POLYNEUROPATHY PLANNED TO INITIATE IN SECOND HALF OF 2019.  Full Article

Alexion Pharmaceuticals Says European Patent Office To Not Grant Co Patent Application Relating To Pharmaceutical Composition Of Soliris
Friday, 6 Sep 2019 

Sept 5 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION PHARMACEUTICALS - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF SOLIRIS (ECULIZUMAB).ALEXION PHARMACEUTICALS INC - WILL EVALUATE OPTION TO APPEAL THE EUROPEAN PATENT OFFICE’S DECISION.ALEXION PHARMA - EUROPEAN PATENT OFFICE TO NOT GRANT CO PATENT APPLICATION RELATING TO PHARMACEUTICAL COMPOSITION OF MATTER OF SOLIRIS (ECULIZUMAB).  Full Article

Alexion Pharmaceuticals Receives Marketing Authorization From EC For Ultomiris For Adults With PNH
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Alexion Pharmaceuticals Inc ::ULTOMIRIS® (RAVULIZUMAB) RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMACEUTICALS - EC APPROVAL BASED ON RESULTS FROM TWO PHASE 3 STUDIES.  Full Article

FDA Grants Approval Of Soliris, A Treatment For Neuromyelitis Optica Spectrum Disorder, To Alexion Pharmaceuticals
Thursday, 27 Jun 2019 

June 27 (Reuters) - FDA::FDA APPROVES FIRST TREATMENT FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER, A RARE AUTOIMMUNE DISEASE OF THE CENTRAL NERVOUS SYSTEM.FDA SAYS GRANTED APPROVAL OF SOLIRIS TO ALEXION PHARMACEUTICALS.FDA SAYS SOLIRIS HAS A BOXED WARNING THAT LIFE-THREATENING AND FATAL MENINGOCOCCAL INFECTIONS HAVE OCCURRED IN PATIENTS TREATED WITH SOLIRIS.  Full Article

Alexion Says FDA Accepted sBLA For Ultomiris Under Priority Review
Thursday, 20 Jun 2019 

June 20 (Reuters) - Alexion Pharmaceuticals Inc ::U.S. FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR ULTOMIRIS® (RAVULIZUMAB-CWVZ) UNDER PRIORITY REVIEW FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS).ALEXION PHARMACEUTICALS INC - FDA SETS TARGET ACTION DATE OF OCTOBER 19, 2019.  Full Article

Alexion Pharma Reports Positive Extension Data From Late-Stage Study of Ultomiris In Patients With Paroxysmal Nocturnal Hemoglobinuria
Friday, 14 Jun 2019 

June 14 (Reuters) - Alexion Pharmaceuticals Inc ::POSITIVE PHASE 3 EXTENSION DATA FOR ULTOMIRIS® (RAVULIZUMAB) IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PRESENTED AT EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS.ALEXION PHARMACEUTICALS INC - ULTOMIRIS DEMONSTRATED CONSISTENT EFFICACY AND SAFETY THROUGH 52 WEEKS.ALEXION PHARMACEUTICALS - SUSTAINED EFFICACY OF ULTOMIRIS WAS OBSERVED ON CO-PRIMARY ENDPOINTS OF TRANSFUSION AVOIDANCE & NORMALIZATION OF LDH LEVELS.ALEXION PHARMACEUTICALS - MOST COMMON ADVERSE EVENTS OCCURRED LESS FREQUENTLY IN EXTENSION PHASE THAN DURING INITIAL TREATMENT PHASE FOR ULTOMIRIS.ALEXION PHARMACEUTICALS - SUSTAINED EFFICACY OF ULTOMIRIS WAS OBSERVED ON SECONDARY ENDPOINTS OF LDH LEVEL REDUCTION AND BREAKTHROUGH HEMOLYSIS.  Full Article

Alexion Pharma rejects Elliott's push for 'proactive sale'

Alexion Pharmaceuticals Inc said on Friday its board of directors had unanimously rejected hedge fund Elliott Management's push for a "proactive sale" process of the entire company because it would not be in the best interest of shareholders.